MedTrace Logo

Soberlink - MAP Outcomes Study Protocol

NCT03190356 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2018-05-15

No results posted yet for this study

Summary

The purpose of this study is to show the effectiveness of Soberlink's remote alcohol monitoring system integrated with MAP's patient engagement platform (EHR) to monitor a sample size of at-risk alcohol use disorder (AUD) population. Ultimately, this data is leveraged to improve clinical outcomes and manage financial risk through facilitating early interventions and other means of mitigating recidivism and costly treatment episodes from AUD population.

Conditions

  • Alcohol Addiction

Interventions

DEVICE

Soberlink Cellular Device

Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.

Sponsors & Collaborators

  • MAP Health Management LLC

    collaborator UNKNOWN

  • Soberlink Healthcare LLC

    lead INDUSTRY

Principal Investigators

  • Shannon Hanrahan, PhD · Shannon Hanrahan

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-22
Primary Completion
2018-04-24
Completion
2018-04-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03190356 on ClinicalTrials.gov